UROGEN PHARMA (NASDAQ:URGN) had its price objective raised by Jefferies Group LLC from $27.00 to $37.00 in a research report report published on Monday. The brokerage currently has a buy rating on the stock.
Other analysts have also recently issued reports about the stock. Oppenheimer Holdings, Inc. set a $32.00 price objective on shares of UROGEN PHARMA and gave the company a buy rating in a research note on Monday, August 14th. Zacks Investment Research upgraded shares of UROGEN PHARMA from a hold rating to a buy rating and set a $20.00 price objective for the company in a research note on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $28.50.
Shares of UROGEN PHARMA (NASDAQ URGN) opened at 30.75 on Monday. UROGEN PHARMA has a one year low of $13.01 and a one year high of $33.77. The firm’s 50-day moving average is $27.98 and its 200-day moving average is $20.83. The stock’s market capitalization is $400.03 million.
TRADEMARK VIOLATION WARNING: “Jefferies Group LLC Boosts UROGEN PHARMA (URGN) Price Target to $37.00” was originally posted by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.themarketsdaily.com/2017/10/12/jefferies-group-llc-boosts-urogen-pharma-urgn-price-target-to-37-00.html.
Several large investors have recently bought and sold shares of the company. FMR LLC purchased a new position in shares of UROGEN PHARMA during the 2nd quarter valued at approximately $13,892,000. Hillhouse Capital Management Ltd. purchased a new position in shares of UROGEN PHARMA during the 2nd quarter valued at approximately $6,363,000. Jennison Associates LLC purchased a new position in shares of UROGEN PHARMA during the 2nd quarter valued at approximately $3,168,000. Wildcat Capital Management LLC purchased a new position in shares of UROGEN PHARMA during the 2nd quarter valued at approximately $2,439,000. Finally, Menora Mivtachim Holdings LTD. purchased a new position in shares of UROGEN PHARMA during the 2nd quarter valued at approximately $2,331,000. 36.06% of the stock is owned by hedge funds and other institutional investors.
UROGEN PHARMA Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Ratings for UROGEN PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UROGEN PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.